

HR 1271

DXM Abuse Prevention Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 1, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 17, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/1271>

Sponsor

Name: Rep. Johnson, Bill [R-OH-6]

Party: Republican • State: OH • Chamber: House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Mar 1, 2017
Rep. Kind, Ron [D-WI-3]	D · WI		Nov 13, 2017
Rep. Meehan, Patrick [R-PA-7]	R · PA		Nov 13, 2017
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Dec 1, 2017
Rep. Tonko, Paul [D-NY-20]	D · NY		Dec 6, 2017
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Jun 5, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 17, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

DXM Abuse Prevention Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to: (1) require a retailer that sells certain drugs containing dextromethorphan (DXM) to have a verification system that is intended to ensure that no one under 18 years of age purchases such drugs from the retailer, (2) establish other restrictions on the sale of over-the-counter drugs containing DXM, and (3) establish restrictions on the distribution of bulk DXM.

Actions Timeline

- **Mar 17, 2017:** Referred to the Subcommittee on Health.
- **Mar 1, 2017:** Introduced in House
- **Mar 1, 2017:** Referred to the House Committee on Energy and Commerce.